NAYA Biosciences, Inc.
NAYA
NASDAQ Global Market2.20
USD
+0.17
- -
CIK
0001417926
ISIN
US44984F6097
CUSIP
44984F609
Return %
Stock
S&P500
1Y
-79.63
26.53
3Y
-99.08
76.60
5Y
-99.79
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Steven M. Shum
- Full Time Employees
- 30
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 5582 Broadcast Court Sarasota United States of America 34240
- IPO Date
- Nov 2, 2020
- CIK
- 0001417926
- Website
- nayabiosciences.com
- Similar Companies
- Business
- NAYA Biosciences, Inc. NAYA Biosciences, Inc. (NASDAQ:NAYA) operates as a diversified life sciences company focused on advancing therapies in oncology, fertility, autoimmune diseases, and regenerative medicine. The company develops and commercializes a portfolio of clinical-stage assets, including NY-303, a GPC3 x NKp46 bifunctional antibody for hepatocellular carcinoma targeting non-responders to standard immunotherapy; NY-338, a CD38 x NKp46 bifunctional antibody for multiple myeloma and autoimmune diseases; NY-500, a PD-1 x VEGF bifunctional antibody for solid tumors; and NY-600, a PSMA x NKp46 bifunctional antibody for metastatic castration-resistant prostate cancer; alongside astatine-211 targeted alpha therapies through its NAYA Therapeutics subsidiary, gene therapy programs for rare mitochondrial diseases such as Leber’s Hereditary Optic Neuropathy acquired from Florida Biotechnologies, and fertility solutions via INVOcell devices and clinic operations. NAYA Biosciences maintains headquarters in Sarasota, Florida, with additional facilities in Miami and Aventura, and conducts operations primarily in the United States while pursuing global partnerships, including recent clinical development collaborations in China. Founded in 2023 through the merger of Clinigence Holdings and 4Front Biotech, the company completed a transformative all-stock merger with INVO Bioscience in October 2024, enabling public trading under the NAYA ticker, enhanced capital access, and integration of fertility clinics with oncology assets; subsequent developments include a strategic decision in April 2025 to separate fertility and oncology businesses, expansion of its oncology pipeline with new PD-1 combinations and NK-cell engagers cleared for Phase 1/2 trials in 2025, partnerships with Alpha Nuclide for China development and Atley Solutions for radiopharmaceutical acceleration, and board nominations to support growth.
INVO Fertility Confirms New Nasdaq Trading Symbol of “IVF”
NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed “INVO Fertility, Inc.”
NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025
NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment
NAYA Biosciences Announces Nomination of New Board Members
INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)